Our Services
Medical Information
Helpful Resources
Published on: 4/24/2026
Rybelsus (semaglutide) is a GLP-1 medication that effectively lowers blood sugar and supports weight loss in adults with type 2 diabetes. However, a small number of users report mood changes or depression while taking it. Possible causes include central nervous system effects, rapid weight loss, shifts in nutrient intake, or pre-existing mental health conditions.
Before switching medications, consider several key factors: the severity of your symptoms, available alternative drugs (such as other GLP-1 agonists, SGLT2 inhibitors, or metformin), and your overall health profile including cardiovascular, kidney, and mental health status.
If you're experiencing mood changes, fatigue, or other symptoms and aren't sure whether Rybelsus is the cause, don't guess—get clarity. Taking a free, instant, online symptom check from Ubie Health can help you understand what may be driving your symptoms, whether they warrant a medication change, and what to discuss with your doctor next. It takes only a few minutes and could save you weeks of uncertainty.
Reviewed for medical accuracy: 07/10/2026
Rybelsus (semaglutide) is an oral glucagon-like peptide-1 receptor agonist (GLP-1 RA) approved for adults with type 2 diabetes. In clinical trials, it has demonstrated significant benefits for blood sugar control and weight loss. Yet, some people taking Rybelsus report mood changes, including depression. If you're asking "why does Rybelsus cause depression?"—you're not alone. This article explores what science tells us, who may be at risk, and when it might make sense to consider alternative medications.
Key takeaways
Rybelsus is the first oral GLP-1 RA. Its main actions:
Common side effects (seen in ≥5% of patients) include:
Most gastrointestinal effects improve over weeks. Rarely, serious events such as pancreatitis can occur.
Clinical trials for semaglutide (oral and injectable forms) did not show a clear, direct cause-and-effect link between Rybelsus and depression. Nevertheless, a small subset of users report mood disturbances. Possible explanations include:
Central Nervous System (CNS) Effects
Rapid Weight Loss and Body Image Shifts
Nutrient Intake and Appetite Suppression
Underlying Mental Health Conditions
Drug Interactions
Data from the PIONEER trials (oral semaglutide) and SUSTAIN trials (injectable semaglutide) offer insight:
Limitations
Depression is more than feeling sad. Watch for:
If you're experiencing any of these warning signs, take a few minutes to complete Ubie's free AI-powered symptom checker for personalized insights about what might be happening and guidance on next steps. Always discuss serious or life-threatening thoughts with a healthcare provider immediately.
Deciding whether to stay on Rybelsus or switch requires balancing benefits and risks. Consider:
Alternative classes include:
Each choice has its own advantages and drawbacks. A personalized plan crafted with your doctor or diabetes specialist offers the best chance of success.
If you want to continue Rybelsus but manage low mood:
Nutrition and Hydration
Exercise and Sleep
Mind-Body Techniques
Social Support
Professional Help
Some symptoms require urgent attention:
If you experience any of these, seek emergency care or call your local crisis hotline. Do not delay.
No two patients are alike. A frank conversation with your prescriber should cover:
Together, you can decide if switching medications or adding mood-support strategies is the right path.
While Rybelsus offers powerful benefits for type 2 diabetes and weight management, a small number of patients report depressive symptoms. The exact reason—whether direct CNS effect, nutritional shifts, rapid weight loss, or unmasked pre-existing mood issues—remains under investigation. If you're wondering "why does Rybelsus cause depression," know that:
Always speak to a doctor before making any changes to your treatment plan—especially if you're experiencing serious or life-threatening symptoms. Your health, both physical and mental, deserves comprehensive care and attention.
(References)
* Chen H, Zhang T, Huang S, Zhu J, Chen X, Liang S. Adverse Events of Semaglutide: A Disproportionality Analysis of the FDA Adverse Event Reporting System (FAERS). Drug Res (Stuttg). 2024 Jan;74(1):34-40. doi: 10.1055/a-2150-1416. Epub 2023 Dec 28. PMID: 38166946.
* Lu C, Tang Y, Huang Z, Li Y, He J, Luo X, Li X. Impact of semaglutide on mental health: A systematic review. Front Endocrinol (Lausanne). 2023 Dec 11;14:1316496. doi: 10.3389/fendo.2023.1316496. PMID: 38102375; PMCID: PMC10745582.
* Patorno E, Fralick M, Kaelber DC, et al. Investigating potential adverse mental health outcomes associated with GLP-1 receptor agonists: a population-based cohort study. Nature Medicine. 2023 Oct;29(10):2483-2491. doi: 10.1038/s41591-023-02540-8. PMID: 37798369.
* Hou C, Zhao H, Fan D, Guo Y, Zhang Z, Wei Z, Xu C, Zhang X, Zhou C. Semaglutide and Psychiatric Adverse Events: A Disproportionality Analysis of the World Health Organization Global Individual Case Safety Report (ICSR) Database. Drug Saf. 2023 Dec;46(12):1277-1284. doi: 10.1007/s40264-023-01369-0. PMID: 38048956.
* Zhang D, Yu S, Zheng H, Li B, Zhang M, Lu M, Chen X. The effect of GLP-1 receptor agonists on psychiatric outcomes: a systematic review and meta-analysis. Front Psychiatry. 2022 Feb 7;13:798544. doi: 10.3389/fpsyt.2022.798544. PMID: 35198889; PMCID: PMC8859941.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.